Evolent Health, Inc (EVH): Price and Financial Metrics

Evolent Health, Inc (EVH)

Today's Latest Price: $6.25 USD

0.11 (-1.73%)

Updated Jun 3 3:02pm

Add EVH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 66 in Medical - Services

See all "A" rated Strong Buy stocks

EVH Stock Summary

  • EVH's went public 5 years ago, making it older than just 17.8% of listed US stocks we're tracking.
  • Over the past twelve months, EVH has reported earnings growth of 332.48%, putting it ahead of 95.99% of US stocks in our set.
  • As for revenue growth, note that EVH's revenue has grown 30.77% over the past 12 months; that beats the revenue growth of 84.37% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Evolent Health Inc, a group of peers worth examining would be NBEV, OPRA, GIFI, DWSN, and CNFR.
  • EVH's SEC filings can be seen here. And to visit Evolent Health Inc's official web site, go to www.evolenthealth.com.
EVH Daily Price Range
EVH 52-Week Price Range

EVH Stock Price Chart More Charts

EVH Price/Volume Stats

Current price $6.25 52-week high $12.01
Prev. close $6.36 52-week low $3.50
Day low $5.82 Volume 3,839,068
Day high $6.57 Avg. volume 1,343,890
50-day MA $6.65 Dividend yield N/A
200-day MA $7.98 Market Cap 529.51M

Evolent Health, Inc (EVH) Company Bio

Evolent Health provides health-care delivery and payment solutions in the United States. The company was founded in 2011 and is based in Arlington, Virginia.

EVH Latest News Stream

Event/TimeNews Detail
Loading, please wait...

EVH Latest Social Stream

Loading social stream, please wait...

View Full EVH Social Stream

Latest EVH News From Around the Web

Below are the latest news stories about Evolent Health Inc that investors may wish to consider to help them evaluate EVH as an investment opportunity.

BioMarin's Positive Hemophilia Data, And Other News: The Good, Bad And Ugly Of Biopharma

BioMarin Provides Positive Clinical Data for Hemophilia Therapy Trial BioMarin Pharmaceutical (BMRN) reported data from its Phase 1/2 clinical trial for valoctocogene roxaparvovec in adults suffering from severe hemophilia A. The company reported that its US marketing application for the drug candidate is currently being reviewed by the FDA, and...

Avisol Capital Partners | June 2, 2020

Here's Why Evolent Health Shares Crashed Today

Shares of Evolent Health (NYSE: EVH) closed down 23% on Monday because the healthcare company's partner, Passport Health Plan, didn't get its Medicaid contract with the state of Kentucky renewed for 2021. The significant portion of revenue we derive from our largest partners, and the potential loss, termination or renegotiation of our relationship or contract with Passport or another significant partner, or multiple partners in the aggregate. Since the contract runs through the end of the year, this year's revenue won't be affected, and Evolent Health reiterated its 2020 revenue guidance of $935 million to $985 million.

Yahoo | June 1, 2020

Evolent comes up empty on Kentucky Medicaid contract

Evolent Health (EVH) reports that the Kentucky Cabinet for Health and Family Services has notified Passport Health Plan, a Louisville-based community health plan that it co-owns with certain Kentucky-based providers, that it has not been awarded a contract to administer Medicaid services for the upcoming three-year contract period beginning January 1,...

Seeking Alpha | May 30, 2020

Evolent Health Partner Passport Health Plan is Not Selected for Kentucky Managed Medicaid Contract

Evolent Health, a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that its partner, Passport Health Plan, received notification from the Kentucky Cabinet for Health and Family Services that Passport has not been awarded a Kentucky Managed Care Organization (MCO) contract for the next contract period, which commences January 1, 2021. Evolent will support Passport in protesting this decision.

Yahoo | May 29, 2020

Evolent Health to Participate in Upcoming Investor Conference

Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Chief Executive Officer and Co-Founder Frank Williams, President and Co-Founder Seth Blackley, and Chief Financial Officer John Johnson will participate in an upcoming investor conference.

Yahoo | May 28, 2020

Read More 'EVH' Stories Here

EVH Price Returns

1-mo -4.43%
3-mo -26.12%
6-mo -19.15%
1-year -39.50%
3-year -75.87%
5-year -66.86%
YTD -30.94%
2019 -54.64%
2018 62.20%
2017 -16.89%
2016 22.21%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9501 seconds.